1. Introduction {#s0005}
===============

Tryptamine is a biogenic amine structurally related to 5-hydroxytryptamine (5-HT) that is generated in the body by neural and peripheral tissues. It is also formed by the microflora in the gastrointestinal tract and is a component of many food items. Tryptamine is implicated in various cardiovascular pathologies, including hypertension, myocardial infarction and migraine. Migraine cluster headaches have been shown to be relieved by psilocybin, a component of magic mushrooms, whose active metabolite, psilocin is a trypamine analogue (N,N-dimethyltryptamine). This action is at a subhallucinogenic dose and likely due to cardiovascular actions ([@bb0285]). The concentration of tryptamine in serum is correlated with that of its precursor [l]{.smallcaps}-tryptophan ([@bb0370]), which is metabolised into tryptamine by aromatic [l]{.smallcaps}-amino acid decarboxylase. Tryptamine is deaminated by monoamine oxidase (MAO) types A and B ([@bb0320]) to indole-3-acetaldehyde, which is subsequently reduced by aldehyde dehydrogenase to indole-3-acetic acid ([@bb0365]).

Tryptamine increases blood pressure ([@bb0135]), an effect that has long been held to be due to indirect sympathomimetic actions, since it may be regarded as a trace amine ([@bb0380]). Indirect sympathomimetic amines release noradrenaline from sympathetic neurones onto vascular α-adrenoceptors to cause vasoconstriction ([@bb0335]). However, in isolated vascular tissues, tryptamine has been shown to cause vasoconstriction of rabbit aorta not by an indirect mechanism but by direct stimulation of both α-adrenoceptors and 5-HT receptors ([@bb0305]). Vasoconstriction by tryptamine has also been demonstrated in rat mesenteric arteries ([@bb0355]), rat caudal arteries ([@bb0170; @bb0080]) and rat aorta ([@bb0145]). [@bb0170] suggested that specific tryptaminergic receptors mediated the vasoconstriction by tryptamine in rat tail arteries. More recently, the vasoconstriction of rat aorta by tryptamine and other trace amines has been shown to be resistant to blockade by α-adrenoceptor and 5-HT antagonists ([@bb0095; @bb0145]). The vasoconstrictor response was attributed ([@bb0095; @bb0090]) to the recently described trace amine-associated receptors (TAARs) ([@bb0075; @bb0100]).

Given the importance of both dietary and endogenous tryptamine in health and disease, there is a paucity of data on the receptors activated by this amine and their signalling pathways in vascular smooth muscle. The few mechanistic studies that do exist have focussed on the phospholipids. In rat cortical slices, tryptamine-induced stimulation of inositol phosphate (IP) accumulation was insensitive to atropine, cyproheptadine, haloperidol, phenoxybenzamine and propranolol indicating that classical neurotransmitter receptors were not involved ([@bb0255]). In a later study, tryptamine activation of primary cultures of rat cerebellar granule cells increased IP turnover, which was not counteracted by atropine, ketanserin and prazosin ([@bb0190]). Subsequently, it was shown that in NIH3T3 fibroblasts stably expressing the 5-HT~2A~ receptor, tryptamine activated the phospholipase C (PLC) and phospholipase A~2~ (PLA~2~) signalling pathways ([@bb0210]).

In the rat mesentery, we have recently demonstrated that tryptamine mediates both vasopressor and vasodepressor responses. The vasoconstrictor response was blocked by the 5-HT antagonists, ritanserin and ketanserin, and is therefore mediated predominantly via 5-HT~2A~ receptors ([@bb0040]). However, there is a clear lack of data on the mechanisms of tryptamine-induced changes in vascular tone, specifically in the resistance size arteries of the mesentery. Based on the knowledge from our mesenteric arterial network studies and the above-mentioned cellular and tissue experiments, we undertook the present investigation to assess the contributions made by selected contractile transduction pathways in tryptamine-derived vascular tone. We also determined the possible roles of co-released vasodepressor transducers in modulating tryptamine-evoked vasoconstriction.

Preliminary accounts of some of these findings have been reported to the British Pharmacological Society ([@bb0030]) and the European Microcirculation Society ([@bb0035]).

2. Materials and methods {#s0010}
========================

2.1. Animal care {#s0015}
----------------

Male Sprague--Dawley rats (250--350 g body weight; Harlan, Bicester, Oxfordshire, U.K.) were housed in temperature (22 ± 1 °C) and humidity (50%) controlled quarters on a 12 h light--dark cycle (07.00--19.00 h light and 19.00--07.00 h dark), 4 animals to a cage, and provided with food and water ad libitum. They were killed by cervical dislocation following stunning in accordance with the Home Office Guidance on the operation of The Animals (Scientific Procedures) Act 1986 (H.M.S.O.), and after local ethical review by the Animal Care and Use Committee of Cardiff University.

2.2. Isolated mesenteric arterial bed {#s0020}
-------------------------------------

The mesenteric vascular bed was exposed through a midline laparotomy incision; the superior mesenteric artery was cleaned of adipose and connective tissues. The artery was cannulated, close to the junction with the abdominal aorta, with a PE-50 polyethylene (BD Intramedic, Oxford, U.K.) cannula, which was ligated and secured with cotton ties, and the mesenteric vascular bed was immediately perfused with Krebs\'--Henseleit-bicarbonate solution, composition in mM: NaCl 118.0, KC1 4.7, NaHCO~3~ 25.0, CaCl~2~ 2.5, KH~2~PO~4~ 1.2, MgSO~4~ 1.2, and glucose 11 (osmolality ≅ 292 mosmol/kg H~2~O), warmed to 37 °C and gassed continuously with 5% CO~2~/95% O~2~ to maintain the pH at 7.4. The initial flow rate was set at 2 ml per minute using a Gilson peristaltic pump to remove blood and metabolites. Simultaneously, the mesenteric bed was excised by gently separating from the gastrointestinal tract (stomach to anterior of rectum), placed in a thermostatic perfusion chamber, and the arterial network was perfused at a constant flow rate (4 ml min^− 1^) that was maintained throughout the experimental procedure ([@bb0220]). Changes in perfusion pressure, a reflection of vascular resistance, were monitored by a pressure transducer (Elcomatic EM 750, Elcomatic Ltd., Glasgow, U.K.) located immediately proximal to the inflow cannula. The transducer was coupled to a PowerLab/4SP computerised data acquisition system (AD Instruments, Charlgrove, Oxon, U.K.) and Chart version 5 software (AD Instruments, U.K.) to display and analyse data. A bubble trap, distal to the cannulated mesentery and proximal to the perfusate solution, removed any air bubbles in the perfusate and also dampened pulses in flow.

2.3. Experimental protocols {#s0025}
---------------------------

After an equilibration period of 1 h, each arterial preparation was subjected to one of the following experimental protocols. Concentrations of signalling pathway inhibitors were chosen based on previously published data. Dose--response curves (DRC) to tryptamine by bolus injection (100 μl volume) were constructed in logarithmic increments in the absence and repeated in the presence of continuous infusion of inhibitors in the same preparation. The response of the preceding dose was permitted to return to the base line before the start of the next incremental dose. Each inhibitor was infused for approximately 20 min prior to the commencement of the subsequent DRC. A 30 min washout interval was allowed between successive dose--response curves.

### 2.3.1. Effects of shear stress {#s0030}

Shear stress, the frictional force generated by blood flow acting on the luminal wall, is known to have a profound effect on the endothelium, and therefore its influence on vascular reactivity ([@bb0130]). Consequently, flow--pressure relationships were determined by incrementally ramping flow rate to achieve a perfusion pressure of 45 mm Hg ([@bb0150]). The flow rate--perfusion pressure relationship was examined in the absence and presence of [l]{.smallcaps}-NAME (100 μM).

### 2.3.2. Drug interventions {#s0035}

To elucidate whether the endothelium could modulate tryptamine-associated vasoconstriction, endothelium denudation was achieved by perfusing distilled water for 4 min through the mesenteric arterial network, followed by perfusion with Kreb\'s solution for 30 min. The extent of endothelium disruption was confirmed by acetylcholine-induced (10^− 7^ M) relaxation of pre-constricted vascular bed (10 μM phenylephrine). Tissues exhibiting inhibition of the acetylcholine-induced vasodilatation by more than 50% were considered acceptable for inclusion in the study.

To examine the roles of 5-HT~2A~ receptors, nitric oxide (NO), monoamine transporters, monoamine oxidases A and B (MAOA/B), phospholipase C (PLC), phospholipase A~2~ (PLA~2~), Rho-kinases (ROCK), cyclooxygenases 1 and 2 (COX1 and COX2), prostanoid receptors (EP~1~ and TP) and prostacyclin synthase (PGI~2~ synthase), DRCs for tryptamine were constructed in the absence and presence of ritanserin (100 pM), [l]{.smallcaps}-NAME (100 μM), cocaine (10 μM), U73122 (synthetic aminosteroid compound, 10 μM), PACOCF~3~ (calcium-independent PLA~2~ antagonist, 10 μM); indomethacin (a non-selective (COX) inhibitor, 10 μM), nimesulide (selective COX-2 antagonist, 10 μM), tranylcypromine (a prostacyclin synthase and non-specific MAOA and MAOB inhibitor, 10 μM), AH 6809 (PGE~2~ receptor (EP~1~ and EP~2~)/less selective PGD~2~ receptor (DP) antagonist, 10 μM), ICI 192,605 (TP receptor antagonist; 10 μM), and the ROCK inhibitors, Y-27,632 (10 μM) and fasudil (also known as HA-1077, 20 μM).

2.4. Data and statistical analysis {#s0040}
----------------------------------

Responses to each dose of tryptamine were measured as the increase in perfusion pressure from the baseline immediately preceding the first dose. Data are expressed as mean ± S.E.M. n indicates the number of animals used. Individual DRCs were plotted as mean increase in perfusion pressure (mm Hg), and the dose--response curves were fitted to a four parameter logistic model to calculate ED~50~ values (the concentration of agonist which produces a response halfway between the baseline and maximum response, E~max~) using FigP (Biosoft, Cambridge, U.K.). From these quantities, geometric means of ED~50~ and E~max~ with 95% confidence limits were computed.

Linear correlation analysis and significances of differences between control and paired E~max~ and ED~50~ values were obtained by paired Student\'s *t*-test. Comparisons of E~max~ and ED~50~ values between different tissues were made by Student\'s unpaired *t*-test, and comparisons between more than two groups were made by ANOVA followed by Tukey\'s multiple comparison test. A *P* value of \< 0.05 was considered to be statistically significant.

2.5. Drugs and chemicals {#s0045}
------------------------

The following drugs were used and were purchased from Tocris (Bristol, U.K.): AH-6809, fasudil, 1-\[6-\[\[(17b)-3-methoxyestra-1,3,5(10)-trie-17-yl\]amino\]hexyl\]-1H-pyrrole-2,5-dione, ICI-192,605 (4-(Z)-6-(2-o-Chlorophenyl-4-o-hydroxyphenyl-1,3-dioxan-cis-5-yl)hexenoic acid), nimesulide, PACOCF~3~ (palmitoyl trifluoromethyl ketone), ritanserin, U73122 and Y-27,632. The following drugs were acquired from Sigma-Aldrich (Poole, UK): acetylcholine, cocaine hydrochloride, 5-hydroxytryptamine (5-HT) hydrochloride, indomethacin \[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid\], [l]{.smallcaps}-NAME (N~ω~-nitro-[l]{.smallcaps}-arginine methyl ester), pargyline, tranylcypromine (trans-2-phenyl-cyclopropylamine hydrochloride), tryptamine hydrochloride, U-46619 (9,11-dideoxy-9a, 11a-methanoepoxy prostaglandin F2a).

All agonists and inhibitors were prepared in distilled water, except indomethacin, U73122, ICI 192,605, ritanserin and PACOCF~3~ which were dissolved in ethanol and AH6809 which was dissolved in 1.1 eq of NaOH. The stock solutions were stored frozen in aliquots, and when required were thawed and diluted. All drug dilutions were made using Krebs\' solution. To eliminate any possible effect of the vehicle on vascular reactivity, the concentration of ethanol used when required was ≤ 0.1% (vol/vol) in the perfusion fluid ([@bb0485]).

3. Results {#s0050}
==========

Basal perfusion pressure was 21.2 ± 0.5 mm Hg for n = 75 animals; unless otherwise indicated, there was no effect of inhibitors on basal perfusion pressure.

3.1. Responses to tryptamine {#s0055}
----------------------------

Tryptamine caused dose-related increases in perfusion pressure. These responses were inhibited in the presence of ritanserin (100 pM) ([Fig. 1](#f0010){ref-type="fig"}A).

3.2. De-endothelialization and inhibition of nitric oxide synthase (NOS) {#s0060}
------------------------------------------------------------------------

On denudation of the mesenteric arteries, the basal perfusion pressure was significantly increased (13 ± 1 vs 18 ± 1 mm Hg, *P* \< 0.01). Moreover, the removal of endothelium augmented the maximum contractile response to tryptamine ([Fig. 1](#f0010){ref-type="fig"}B). In the presence of [l]{.smallcaps}-NAME (100 μM) the constrictor responses to tryptamine were potentiated ([Fig. 1](#f0010){ref-type="fig"}C) and the maximum response was significantly greater than in the control mesenteries ([Table 1](#t0005){ref-type="table"}). When [l]{.smallcaps}-NAME was introduced in the presence of ritanserin (100 pM), small vasoconstrictor responses to tryptamine were reinstated ([Fig. 1](#f0010){ref-type="fig"}D).

To examine the role of shear stress on the perfusion pressure and whether nitric oxide was released by the increasing shear stress during vasoconstrictor responses, the relationship between flow rate and perfusion pressure was examined. Increasing flow rate resulted in a linear increase in perfusion pressure ([Fig. 2](#f0015){ref-type="fig"}). This flow rate--perfusion pressure relationship was identical in the presence of [l]{.smallcaps}-NAME (100 μM) ([Fig. 2](#f0015){ref-type="fig"}).

3.3. Phospholipase and cyclo-oxygenase pathways {#s0065}
-----------------------------------------------

The non-selective phospholipase C inhibitor, U73122 (1 μM), abolished the tryptamine-induced vasoconstrictor responses of the mesenteric arteries ([Fig. 3](#f0020){ref-type="fig"}A and [Table 1](#t0005){ref-type="table"}), and it was not possible to ascertain an ED~50~ value. The competitive phospholipase A~2~ (iPLA~2~) inhibitor, PACOCF~3~, also antagonised the responses to tryptamine as a shift of the DRC to the right ([Fig. 3](#f0020){ref-type="fig"}B), reflected by the reduced potency ([Table 1](#t0005){ref-type="table"}). Indomethacin (a non-specific COX inhibitor) almost completely abolished the vasoconstrictor responses to tryptamine ([Fig. 3](#f0020){ref-type="fig"}C), precluding determination of an ED~50~ value. Nimesulide, a specific COX-2 inhibitor, significantly attenuated the maximum response from 45 ± 1 to 22 ± 2 mm Hg ([Fig. 3](#f0020){ref-type="fig"}D).

3.4. Prostanoid receptors {#s0070}
-------------------------

The EP~1~ prostanoid receptor inhibitor, AH6809 (10 μM), shifted the DRC for tryptamine to the right and significantly increased the ED~50~ value ([Fig. 4](#f0025){ref-type="fig"}A). Tranylcypromine (a prostacyclin synthase inhibitor and non-selective MAO-A and MAO-B inhibitor) increased the sensitivity to tryptamine only at the lower concentrations ([Fig. 4](#f0025){ref-type="fig"}B). The potency and maximum responses of the mesenteric arterial bed to tryptamine were unaltered in the presence of the thromboxane TP receptor antagonist ICI 192,605 ([Fig. 4](#f0025){ref-type="fig"}C).

3.5. Rho-kinase inhibitors {#s0075}
--------------------------

The tryptamine-dependent vasoconstriction was inhibited by the Rho/Rho-kinase inhibitors. The maximum response to tryptamine was significantly inhibited to 45% by Y-27632 ([Fig. 5](#f0030){ref-type="fig"}A) and to 65% by fasudil ([Fig. 5](#f0030){ref-type="fig"}B).

3.6. Monoamine transporter {#s0080}
--------------------------

The presence of the neuronal amine transport inhibitor, cocaine (10 μM), significantly enhanced the tryptamine vasoconstrictor responses without altering the sensitivity ([Fig. 6](#f0035){ref-type="fig"}A and [Table 1](#t0005){ref-type="table"}). When cocaine (10 μM) and [l]{.smallcaps}-NAME (100 μM) were combined, there was an additional potentiation, the maximum vasoconstriction reaching 126.4 ± 6.9 mm Hg, which was significantly greater than with [l]{.smallcaps}-NAME alone (90.1 ± 10.3 mm Hg).

4. Discussion {#s0085}
=============

This study has confirmed previous reports that tryptamine exerts vasoconstrictor properties in the rat isolated mesenteric arteries ([@bb0355]) and in the rat isolated perfused mesenteric arterial bed ([@bb0040]). Tryptamine also causes vasoconstriction in rat ([@bb0145]) and rabbit ([@bb0305]) aorta and rat caudal arteries ([@bb0170; @bb0080]). This response would explain the increases in blood pressure observed when trypamine is administered to dogs ([@bb0135]). The tryptamine induced pressor response of the mesenteric bed was inhibited by the 5-HT~2A~ receptor antagonist, ritanserin, indicating that the vasoconstriction is largely via activation of 5-HT~2A~ receptors. This is at variance with the vasoconstriction in other vessels such as the rat aorta where the vasoconstriction by tryptamine is not inhibited by another 5-HT~2A~ receptor antagonist, ketanserin ([@bb0145]), although in the rabbit aorta ([@bb0305]) and rat tail artery ([@bb0080]), 5-HT antagonists were effective. The main aim of this study was to determine the signalling pathways for this 5-HT~2A~-mediated vasoconstriction by tryptamine by the use of appropriate inhibitors. Secondly, we examined whether the response was modulated through co-activation of relaxant signalling mechanisms.

4.1. Contractile transducers {#s0145}
----------------------------

### 4.1.1. Phospholipid signalling cascades {#s0095}

Activation of G protein-coupled receptors, such as 5-HT~2A~ receptors, stimulates phospholipase C, the catalysed products of which funnel out to further amplify downstream signalling transducers of smooth muscle contractile responses. Stimulation of phospholipase C catalyses the hydrolysis of the phosphorylated lipid, phosphatidylinositol 4, 5-bisphosphate (PIP~2~) to produce second messengers, inositol 1, 4, 5-trisphosphate (IP~3~) and diacylglycerol (DAG), ([@bb0260], [Fig. 7](#f0040){ref-type="fig"}). IP~3~ through the activation of IP~3~ receptors (IP~3~Rs), located on store-operated calcium channels, mobilises calcium into the cytosol from intracellular stores (sarcoplasmic/endoplasmic reticulum, Golgi complex and the nuclear envelope), leading to contraction ([@bb0050]). Tryptamine activates heterotrimeric G protein-coupled 5-HT~2A~ receptors, which are linked to the PLC signalling system since the contractile response was completely eliminated by U73122, a putative blocker of PLC ([@bb0480]). DAG, the other transducer arising from PLC activation, stimulates protein kinase C (PKC), ([@bb0250]). DAG activation of PKC is the initial step in the prostaglandin biosynthetic pathway initiated by activation of a family of phospholipase A~2~ (PLA~2~) isozymes \[secretory PLA~2~s (sPLA~2~), the cytosolic PLA~2~s (cPLA~2~), calcium-independent PLA~2~s (iPLA~2~) and the platelet activating factor (PAF) acid hydrolases\]. These are primarily responsible for agonist-induced hydrolysis of the sn-2 ester bonds in membrane phospholipids, such as phosphotidyl choline and phosphotidylethanolamines, releasing arachidonic acid and lysophospholipids ([@bb0275]; [Fig. 7](#f0040){ref-type="fig"}).

The present investigation has shown that a Ca^2 +^-independent PLA~2~ is involved in tryptamine-induced vasoconstriction, since the response was significantly attenuated by the iPLA~2~ inhibitor, PACOCF~3~. Previous studies have confirmed the iPLA~2~ blocking activity of PACOCF~3~ ([@bb0005]) and demonstrated the PKC-dependent promoting activity of calcium-independent phospholipase A~2~ β (iPLA~2~β, group VIB PLA~2~) and liberation of arachidonic acid ([@bb0200; @bb0015]). Moreover, diacylglycerol has been shown to be a substrate for DAG lipase, which leads to the synthesis of 2-arachidonylglycerol, which is metabolised by monoacylglycerol lipase or fatty acid amidohydrolase to also yield arachidonic acid ([@bb0315]).

Interestingly, our results differ from the 5-HT~2A~ receptor-mediated PLC and PLA~2~ signalling pathways in NIH3T3--5HT~2A~ fibroblast cells, which are independently coupled to the receptor ([@bb0210]). This is perhaps due to *a*. overexpression of the receptor in NIH3T3 fibroblasts, *b*. the different cell types involved, or *c*. the static milieu of cell culture as opposed to the dynamic environment of the perfused isolated vascular bed.

### 4.1.2. Cyclooxygenases {#s0100}

Conversion of arachidonic acid to PGG~2~ is via a cyclooxygenase reaction, which is followed by a peroxidase reaction to PGH~2~, these are the committed steps in prostanoid biosynthesis, and both are mediated by two prostaglandin synthases or cyclooxygenases (COX-1 and COX-2) ([@bb0295]).

Cyclooxygenases play a pivotal role in prostaglandin and/or thromboxane synthesis and their consequent vasoconstrictor effects ([@bb0295]). The present study implicates both COX isoforms as constitutive enzymes in mediating vasoconstriction of the mesenteric arteries by tryptamine. The non-selective COX inhibitor, indomethacin, virtually abolished the vasoconstrictor responses to tryptamine whereas the COX-2-selective inhibitor, nimesulide, only halved the maximum response. This leads to the conclusion that both isoforms are involved in the vasoconstrictor response. Previous reports of expression of the two COX isozymes in different tissues, including the vasculature, from human and animal studies are in accord with our results ([@bb0140; @bb0350; @bb0175; @bb0330]). It is important to note that the abolition of the vasopressor responses by indomethacin indicates that the lipoxygenase and the cytochrome P-450 monoxygenase pathways are not involved in the tryptamine-mediated vasoconstriction.

### 4.1.3. Prostanoids {#s0105}

The PGH~2~ derived from cyclooxygenase activation is subsequently converted to a variety of bioactive prostanoids, such as thromboxane (TxA~2~) and prostaglandins F~2α~, D~2~, E~2~ and I~2~ (prostacyclin), depending on the downstream enzymatic machinery present in a particular cell type ([@bb0120; @bb0085]). Prostaglandin PGE~2~ has been implicated in a plethora of physiological processes in vascular smooth muscle and endothelial cells, including vascular tone, cellular signalling, proliferation, migration and tubulogenesis ([@bb0310]). PGE~2~ exerts the majority of these pleiotropic actions in diverse tissues through a family of four G protein-coupled heptahelical cell surface receptors (EP~1~ to EP~4~), ([@bb0240]). The EP~1~ receptor antagonist, AH-6809, significantly inhibited the tryptamine-induced vasoconstriction, illustrating that PGE~2~ is probably the main prostanoid generated which induces tryptamine vasoconstriction in the mesenteric arterial bed via EP~1~ receptors. Stimulation of the EP~1~ receptor, through a G~q~ protein, activates PLC/inositol triphosphate and protein kinase C (PKC) signalling and is coupled to intracellular Ca^2 +^ elevation ([@bb0060]), resulting in vasoconstriction ([Fig. 7](#f0040){ref-type="fig"}). In support of a role for EP~1~ receptors in mediating vasoconstrictor responses, PGE~2~- and 17-phenyl-trinor-PGE~2~ (selective EP~1~ receptor agonist)-induced vasoconstriction in isolated pressurised gracilis muscle arterioles of db/db mice was attenuated by pre-treatment with AH6809 ([@bb0265]). We next examined whether thromboxanes and thromboxane receptors (TP) were involved in the vasoconstrictor response. The thromboxane receptor inhibitor ICI 192,605 had no effect on the vasoconstrictor responses to tryptamine. Previous studies have shown that vasoconstriction of rat mesenteric arteries by PGE~2~ was unaffected by the thromboxane A~2~ (TxA~2~) receptor blocker SQ 29,548, whereas the response to PGF~2α~ was abolished. The thromboxane A~2~ mimetic, U-46619, also contracted the rat mesenteric resistance arteries but was inhibited by an EP~1~ receptor antagonist (SC-19220) and attributed to release of PGE~2~ by U-46619 into the mesenteric perfusate ([@bb0065]). A link can therefore be established in the vasoconstrictor response to tryptamine between activation of phospholipases C and A~2~, liberation of arachidonic acid and generation of the vasoconstrictor prostaglandin E~2~ via cyclooxygenase. A similar link has been shown in cultures of A-10 vascular smooth muscle cells isolated from wild-type mice, where iPLA~2~β catalysed the liberation of arachidonic acid which binds to COX-2 to produce PGE~2~. In contrast, the concentration of PGE~2~ was dramatically reduced in media obtained from iPLA~2~β-null mice VSMC cultures ([@bb0235]). Thus, tryptamine-induced contraction appears to be mediated via the prostanoid PGE~2~ through EP~1~ receptors, but there is no participation of thromboxanes or receptors for TxA~2~.

### 4.1.4. Rho-kinases {#s0110}

Heterotrimeric G-proteins of the Gα~12~ and Gα~13~ family transduce signals emanating from GPCRs to activate the low molecular weight guanosine triphosphate (GTP)-binding protein RhoA, a member of the Ras family of proteins, and its downstream target, Rho-kinase (a p160 Rho-associated coiled-coil-containing protein kinase, a serine/threonine specific kinase). Rho-kinase has 2 isoforms: ROKα/ROCKII and ROKβ/ROCKI, which are important regulators of vascular tone ([@bb0300]). During this calcium-independent process, Rho-kinase causes inhibition of myosin light chain phosphatase activity by phosphorylation of its myosin-binding subunit (a regulatory domain), resulting in elevated vascular tension. This phenomenon is referred to as calcium sensitisation ([@bb0345]).

We have demonstrated that the 5-HT~2A~ receptors stimulated by tryptamine are coupled to the Rho/ROCK signalling pathway by way of attenuation of the vasoconstrictor response to tryptamine by fasudil (active component: hydroxyfasudil) and Y-27632. Fasudil and Y-27632 block the activity of Rho-kinase by competing with the ATP-binding site on the enzyme ([@bb0195]).

4.2. Dilator mediators {#s0115}
----------------------

### 4.2.1. Nitric oxide {#s0120}

Inhibition of NO release with the nitric oxide synthase inhibitor, [l]{.smallcaps}-NAME, caused almost three-fold increase in the maximum vasoconstriction of the rat mesentery by tryptamine. Similarly, endothelium denudation potentiated the maximum response. The heterotrimeric G protein Gα~12~ is coupled to eNOS leading to elevated intracellular concentrations of eNOS ([@bb0020]). The effects of NO are mediated primarily through the direct activation of soluble guanylate cyclase, generating cyclic guanosine monophosphate (cGMP) ([@bb0025; @bb0215]), which stimulates protein kinase G (PKG, also termed cGMP-targeted kinase, cGK), which can suppress Gα~q~ stimulation by interaction with regulator of G-protein coupled signalling 2 (RGS2) ([@bb0180]). To note, vasodilation of mice aortic rings by PGE~2~ interaction with the EP~4~ receptor results in NO formation ([@bb0185]). The high bioavailability of NO counteracts the contractile actions of COX-metabolites ([@bb0230]) and Rho-kinase ([@bb0270]). Consequently, NO serves as a homeostatic buffer against incremental or excessive vasoconstriction and smoothes out excessive fluctuations in blood pressure.

When NO was inhibited by [l]{.smallcaps}-NAME after blockade of the tryptamine vasoconstriction by the 5-HT~2A~ antagonist, ritanserin, small vasoconstrictor responses were restored. These cannot be due to 5-HT~2A~ receptor stimulation overcoming the ritanserin blockade as the doses of tryptamine are unchanged. Our previous study showed that in the presence of 5-HT~2A~ receptor blockade and with perfusion pressure raised by perfusion with phenylephrine, tryptamine causes dose-related vasodilatation which is NO-mediated ([@bb0040]). When this vasodilator action is removed by [l]{.smallcaps}-NAME, a vasoconstriction appears. This was not examined further but may be due to activation of trace amine-associated receptors, which appear to mediate vasoconstrictor responses to tryptamine and other trace amines in other blood vessels such as coronary arteries ([@bb0165]) and rat aorta ([@bb0145]).

### 4.2.2. Shear stress {#s0125}

According to the Hagen--Poiseuille equation, vascular resistance is a function of vascular geometry (radius and length of vessel) and viscosity of fluid (η). The resistance of a blood vessel is related to the inverse of the fourth power of vessel diameter and therefore small reductions in diameter have significant consequences for vascular resistance. Graded increases in flow rate through the rat mesenteric bed induced by raising the pump flow rate were associated with corresponding rises in perfusion pressure. This is a reflection of an increase in vascular smooth muscle tone due to elevations in wall shear stresses, which leads to an increase in vascular resistance. The possibility was considered that these increases in shear stress might cause release of vasodilator NO which could dampen the pressure increases. However, inhibition of NO synthesis with [l]{.smallcaps}-NAME had no influence on flow rate--perfusion pressure relationship. Our results are consistent with the findings of unchanged perfusion pressure after incubation with [l]{.smallcaps}-NAME in the non-pregnant rat isolated uterine bed ([@bb0150]) and non-pregnant rat isolated perfused mesenteric arteries ([@bb0115]). However, they contrast with flow experiments on cultured endothelial cells ([@bb0205]), where NO was found to be released. Therefore, in our study NO release can be attributed to tryptamine stimulation of post-receptor pathways and not as a result of any shear forces exerted on the luminal wall by the vasoconstriction. The possibility, however, arises that increasing perfusion pressure by pump-mediated increases in flow does not entirely mimic the increase due to vasoconstriction. The possibility must be considered that a part of the NO release by tryptamine results from conformational changes of endothelial cells arising from vasoconstriction. The effects of [l]{.smallcaps}-NAME on a wider range of vasoconstrictor agents acting via different receptors would be required to test this idea further.

It is worth mentioning that links have been established between nitric oxide and the Rho-kinase signal transduction pathways. NO can cause vasodilatation through inhibition of the RhoA/Rho-kinase (ROCK) signalling pathway in vascular smooth muscle ([@bb0270]), rat coelic artery ([@bb0340]) and rat aorta ([@bb0110]). On the other hand, the RhoA/Rho-kinase pathway prevents protein kinase B/Akt-dependent eNOS activity in human endothelial cells ([@bb0225]). A more recent study has provided evidence that Rho-kinase signalling activity was amplified in endothelial nitric oxide synthase (eNOS) null mice ([@bb0360]). Further complexity arises from results suggesting that arachidonic acid generated by phospholipids can activate ROCK ([@bb0045; @bb0155]), and perhaps contribute to Ca^2 +^-sensitization by tryptamine.

### 4.2.3. Prostacyclin {#s0130}

Prostacyclin (PGI~2~) is a vasodilator prostanoid produced by endothelial cells as a key mediator in the regulation of vascular tone and blood pressure. Thus potentiation of the tryptamine-elicited vasoconstriction by endothelial cell denudation can be partly explained by removal of prostacyclin as well as removal of vasodilator nitric oxide. PGI~2~ exerts its cellular effects by binding to a G protein-coupled receptor, IP. Stimulation of the IP receptor, coupled to G~s~-type G protein, activates adenylate cyclase leading to cAMP formation, and therefore to vasodilatation of the mesenteric vessels ([@bb0160]). We examined whether tryptamine would release prostacyclin by use of a potent prostacyclin synthase antagonist, tranylcypromine ([@bb0375]). The vasoconstrictor response was augmented at the lower doses of tryptamine, suggesting that at lower concentrations prostacyclin was indeed released by tryptamine. However, tranylcypromine is also a non-selective inhibitor of monoamine oxidases (MAO) A and B ([@bb0055]). MAO A and B activities appear to be associated with the mesenteric arteries of various species ([@bb0125; @bb0105]). Thus, an alternative explanation for the enhanced responses at lower doses is that tryptamine is metabolised by MAO in the mesenteric bed and its inhibition by tranylcypromine allows elevated levels to reach the receptors.

4.3. Monoamine transporters {#s0135}
---------------------------

Cocaine is a nonselective, competitive inhibitor of monoamine reuptake, inhibiting the dopamine (DAT), noradrenaline (NAT) and 5-HT (serotonin, SERT) transporters with K~i~ values of 267 nM, 872 nM and 392 nM, respectively ([@bb0325]). Therefore, cocaine is over 2-fold more potent at the serotonin than the noradrenaline transporter. Tryptamine is a substrate for the serotonin transporter ([@bb0280; @bb0010]) and mesenteric arteries are known to express the SERT ([@bb0245]). Thus, inhibition of the transporter would be expected to increase the tryptamine concentration in mesenteric circulation. Indeed, cocaine moderately potentiated the contractile response of mesenteric arteries to tryptamine. When cocaine was combined with [l]{.smallcaps}-NAME, there was an additional potentiation which we assume is due to the combined additive effects of inhibition of tryptamine transport and removal of the opposing vasodilator effects of released NO. There is one recent report of regulation of nitric oxide enhancing the activity of the noradrenaline transporter to control blood pressure responses to tyramine in anaesthetized rats ([@bb0290]). However, this does not appear to apply to tryptamine responses here, as [l]{.smallcaps}-NAME would have opposed the action of cocaine rather than enhancing it.

4.4. Summary {#s0140}
------------

In summary, tryptamine causes vasoconstriction of rat mesenteric arterial beds which is mediated via 5-HT~2A~ receptors. This response is due to a coupling between the tryptaminergic receptors, phospholipases C and A~2~ and contractile prostaglandins (PGE~2~). Signalling through the RhoA/ROCK pathway is also implicated. There is a simultaneous release of vasodilator nitric oxide and possibly prostacyclin from the endothelium which oppose and homeostatically balance the increases in pressure. Thus, circulating levels of tryptamine derived from endogenous synthesis or from dietary intake can exert a regulatory control of mesenteric blood flow and thus the digestive and absorptive activities of the gastrointestinal tract.
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![Dose--response curves for increases in perfusion pressure by tryptamine of rat isolated perfused mesenteric arterial bed. Doses of tryptamine were administered as individual boluses (nmoles/100 μl). Each response is the mean ± S.E.M. increase in perfusion pressure. A. Dose--response curves for vasoconstrictor responses to tryptamine in the absence (□) and repeated in the presence (■, n = 3) of ritanserin (100 pM). \* Significantly different from the absence of ritanserin, *P* \< 0.05. B. Dose--response curves for tryptamine with intact endothelium (□, n = 4) and in de-endothelialised (■, n = 4) mesenteric arterial bed. \* Significantly different from intact endothelium, *P* \< 0.05. C. Dose--response curves in the absence (□) and presence (■, n = 7) of [l]{.smallcaps}-NAME (100 μM). All points significantly different between tryptamine alone and with [l]{.smallcaps}-NAME, *P* \< 0.05. D. Dose--response curves in the presence of ritanserin (◆, 100 pM) and in the additional presence (▲, n = 3) of [l]{.smallcaps}-NAME (100 μM). \* Significantly greater than ritanserin alone, *P* \< 0.05, \*\* P \< 0.01.](gr1){#f0010}

![Correlation between flow rate and increase in perfusion pressure in rat isolated perfused mesenteric arterial bed in the absence (⋄, n = 6, y = 4.9 × − 1.32, r^2^ = 0.99) and presence (□, n = 6, y = 4.90 × − 0.86, r^2^ = 0.99) of [l]{.smallcaps}-NAME (100 μM).](gr2){#f0015}

![Effects of phospholipase and COX inhibitors on dose--response curves for tryptamine-induced vasoconstriction of rat isolated perfused mesentery. Dose--response curves in the absence (□) and presence (■) of A. phospholipase C inhibitor, U73,122 (10 μM, n = 4), B. phospholipase A~2~ inhibitor, PACOCF~3~ (10 μM, n = 3), C. COX-1/COX-2 inhibitor, indomethacin (10 μM, n = 5), and D. COX-2 inhibitor, nimesulide (10 μM, n = 3). \* Significantly different points from tryptamine alone, *P* \< 0.05, \*\* *P* \< 0.01. Each response is the mean ± S.E.M. increase in perfusion pressure.](gr3){#f0020}

![Effects of prostanoid inhibitors on dose--response curves for tryptamine-induced vasoconstriction of rat isolated perfused mesentery. Dose--response curves in the absence (□) and presence (■) of A. prostaglandin EP~1~ receptor antagonist, AH-6809 (10 μM, n = 4), B. prostacyclin synthase/MAO inhibitor, tranylcypromine (10 μM, n = 5), and C. thromboxane TP receptor antagonist, ICI 192,605 (1 μM, n = 4). \* Significantly different points from tryptamine alone, *P* \< 0.05, \*\* *P* \< 0.01. Each response is the mean ± S.E.M. increase in perfusion pressure.](gr4){#f0025}

![Effects of Rho-kinase inhibitors on dose--response curves for tryptamine-induced vasoconstriction of rat isolated perfused mesentery. Dose--response curves in the absence (□) and presence (■) of A. Y-27632 (10 μM, n = 3) and B. fasudil (HA-1077, 20 μM, n = 3). \* Significantly different from tryptamine alone, *P* \< 0.05, \*\* *P* \< 0.01. Each response is the mean ± S.E.M. increase in perfusion pressure.](gr5){#f0030}

![Effects of the monoamine transport inhibitor, cocaine, on dose--response curves for tryptamine-induced vasoconstriction of rat isolated perfused mesentery. Dose--response curves in the absence (□) and presence (■) of cocaine (10 μM, n = 4) and, in separate experiments (B.), in the additional presence (♦) of [l]{.smallcaps}-NAME (100 μM, n = 4). All points in A. significantly different between tryptamine alone and with cocaine, *P* \< 0.05. In B. \* Significantly different from tryptamine alone, *P* \< 0.05, \*\* *P* \< 0.01, \*\*\* *P* \< 0.001. Each response is the mean ± S.E.M. increase in perfusion pressure.](gr6){#f0035}

![Schematic diagram showing the proposed signal transduction pathways for the vasoconstrictor and vasodilator responses to tryptamine of rat isolated mesenteric vascular bed mediated via 5-HT~2A~ and trace amine-associated receptors (TAAR), respectively. Inhibitors of signalling intermediates are shown in italics and their site of interaction by a red cross (![](fx2.gif)).](gr7){#f0040}

###### 

Potency and maximum vasoconstrictor responses for tryptamine in the absence and presence of inhibitors in the rat isolated perfused mesenteric arterial beds.

  ---------------------------------------------------------------------------------------
  Signalling pathway and inhibitor     Potency\                 Maximum effects\      n
                                       (ED~50~, nmol/100 μl)    (E~max~, mm Hg)       
  ------------------------------------ ------------------------ --------------------- ---
  5-HT~2A~ receptors                                                                  

   Control                             32.0 (22.4--45.6)        37.3 ± 3.3            9

   Ritanserin (100 pM)                 103.9 (14.2--760)        2.0 ± 0.4^\$\$^       3

  Nitric oxide synthase                                                               

   Control                             35.2 (25.9--47.8)        32 ± 3                7

   [l]{.smallcaps}-NAME (100 μM)       33.4 (17.4--64.2)        90.1 ± 10.3^⁎⁎⁎^      7

   [l]{.smallcaps}-NAME + ritanserin   9.0 (1.3--61.0)          8.6 ± 1.2             3

  Denudation                                                                          

   + Endothelium                       81.0 (63.3--103.5)       12.4 ± 1.5            4

   − Endothelium                       96.8 (24.7--379.2)       20.0 ± 2.3^⁎^         4

  Monoamine transporter                                                               

   Control                             46.9 (33.7--65.4)        27 ± 1                4

   Cocaine (10^− 5^ M)                 46.4 (33.2--64. 7)       51 ± 3^⁎⁎^            4

   Cocaine + [l]{.smallcaps}-NAME      22.1 (6.5--75.5)^\#\#^   126.4 ± 6.9^\#\#\#^   4

  Phospholipase C                                                                     

   Control                             38.8 (24.1--62.5)        43 ± 6                4

   U73,122 (10^− 5^ M)                 ND                       8.6 ± 1.7^⁎⁎^         4

  Phospholipase A~2~                                                                  

   Control                             29.6 (12.8--68.4)        18 ± 2                3

   PACOCF~3~ (10^− 5^ M)               92.1 (55.5--152.8)^⁎^    18 ± 2                3

  Rho-kinase                                                                          

   Control                             26.2 (12.5--54.7)        20 ± 4                3

   Y-27,632 (10^− 5^ M)                18.9 (5.9--61.0)         11 ± 3^⁎⁎^            3

   Control                             27.50 (13.24--57.1)      26 ± 3                3

   Fasudil (2 × 10^− 5^ M)             18.9 (4.3--82.6)         9 ± 1^⁎⁎^             3

  COX-1 and COX-2                                                                     

   Control                             29.2 (17.0--50.1)        25 ± 3                5

   Indomethacin (10^− 5^ M)            ND                       10.4 ± 1.7^⁎⁎^        5

  COX-2                                                                               

   Control                             28.9 (12.7--65.7)        45 ± 1                3

   Nimesulide (10^− 5^ M)              57.6 (52.7--63.0)^⁎^     22 ± 2^⁎⁎^            3

  Prostanoid EP~1~ receptor                                                           

   Control                             32.0 (21.1--48.7)        20 ± 3                4

   AH-6809 (10^− 5^ M)                 49.0 (32.6--73.7)\*      14 ± 3                4

  Prostacyclin synthase/MAO                                                           

   Control                             29.4 (21.2--40.8)        28 ± 7                5

   Tranylcypromine (10^− 5^ M)         20.1 (14.1--28.6)^⁎^     27 ± 3                5

  Thromboxane TP receptor                                                             

   Control                             29.8 (20.5--43.4)        24 ± 5                4

   ICI 192605 (10^− 6^ M)              28.8 (15.6--53.5)        27 ± 5                4
  ---------------------------------------------------------------------------------------

Potency is represented as the geometric mean (with 95% confidence intervals) ED~50~ (nmole/100 μl) and the maximum response is displayed as arithmetic mean ± S.E.M maximum increase in perfusion pressure (mm Hg). n is the number of animals. \* Represents significant differences from paired control values by Student\'s paired *t*-test, *P* \< 0.05, \*\* *P* \< 0.01 and \*\*\* *P* \< 0.001. ^\$\$^ Significant difference from unpaired controls by Student\'s unpaired *t*-test, *P* \< 0.01. ^\#\#^ Significant differences between the [l]{.smallcaps}-NAME plus cocaine group and control or cocaine alone by one-way ANOVA with Tukey\'s multiple comparison test, *P* \< 0.003, ^\#\#\#^*P* \< 0.0001. ND, not determined.
